Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors

Abstract

Node positive head and neck squamous cell carcinomas (HNSCCs) patients exhibit worse outcomes in terms of regional neck control, risk for distant metastases and overall survival. Smaller non-palpable lymph nodes may be inflammatory or may harbor clinically occult metastases, a characterization that can be challenging to make using routine imaging modalities. Ferumoxytol has been previously investigated as an intra-tumoral contrast agent for magnetic resonance imaging (MRI) for intracranial malignancies and lymph node agent in prostate cancer. Hence, our group was motivated to carry out a prospective feasibility study to assess the feasibility of ferumoxytol dynamic contrast enhanced (DCE)weighted MRI relative to that of gadolinium-based DCE-MRI for nodal and primary tumor imaging in patients with biopsy-proven node-positive HNSCC or melanoma. although this institutional review board (IRB)-approved study was prematurely terminated because of an FDa black box warning, the investigators sought to curate and publish this unique dataset of matched clinical, and anatomical and DCE MRI data for the enrolled five patients to be available for scientists interested in molecular imaging. Record System), a custom-built electronic medical record system by MDACC, that started in 1999 with subsequent significant improvement in 2007 that allowed further new capabilities, such as integrating research data and accessing data from virtually every electronic source within the institution, thus serving a great role in patient care and research. http://www.clinfowiki.org/wiki/index.php/ ClinicStation. ClinicStation (Electronic Medical Usage NotesWe invite all interested researchers to download this dataset of matched clinical-imaging dataset including DCE/ DSC-weighted perfusion MRI acquisitions in immobilization position using an under-investigated contrast agent in the setting of HNSCC imaging. Moreover, this data descriptor serves as a report for the only trial that prospectively investigated the feasibility of USPIO as a contrast agent for DCE-MRI acquisition purposes in the setting of head and neck cancer imaging.

Iron Oxide Nanoparticles in Mesenchymal Stem Cell Detection and Therapy

“…A subsequent study aimed to assess the feasibility of Ferumoxytol dynamic contrast enhanced-weighted MRI relative to gadolinium-based dynamic contrast enhanced-MRI for nodal and tumour imaging in five patients with head and neck squamous cell carcinomas. However, this study was prematurely terminated because of FDA black box warning [ 81 ].…”

Iron-Based Magnetic Nanosystems for Diagnostic Imaging and Drug Delivery: Towards Transformative Biomedical Applications

“…MR signal demonstrated an increase with incubation time for T 1 -weighted images and a decrease in T 2 -weighted images with the SNR in the T 1 images decreasing slowly with time with peak signal at 12 h with no T 2 enhancement happening concurrently. The ability of the nanoparticles to present T 1 or T 2 enhancement was found to depend upon the particle size, although the aggregation of the nanoparticles was found to affect both transverse and longitudinal relaxation in MRI [ 40 ]. It is postulated that the IONP-HP clusters aggravate the proton dephasing of surrounding water molecules; thus, the T 2 contrast effect is enhanced by the variety of sizes within the cluster.…”

“…However, there is large opportunity for growth to access these regions allowing for the full implementation of medical imaging through advancing technologies and targeting the applicability of MRI at lower field strengths. Some of the hurdles include developing instrumentation that can be used in an unshielded environment, has less energy requirements, and can be operated and analyzed via telemedicine to truly address accessibility constraints seen presently [ 40 ]. Fortunately, work has already begun to address the need for smaller and potentially portable MR spectrometers, with additional investigation into the utilization of ultra-low-field, and very-low-field MRI in these underrepresented demographics.…”

Iron Oxide Nanoparticles: Physicochemical Characteristics and Historical Developments to Commercialization for Potential Technological Applications

“…Resovist, a commercial dextran-coated Fe 3 O 4 ferrofluid developed for contrast-enhanced MRI of the liver, revealed side effects such as headache and irritation at the site of injection in only a small number of patients. In another study assessing the toxicity profile of ferumoxytol and ferumoxtran, commercial polyglucose sorbitol carboxymethyl ether-coated IONPs developed for angiography, less than 1% of patients exhibited serious side effects (such as chest pain, hypotension, and dyspnea) while 10–20% of patients exhibited moderate adverse events (such as headache back pain, and urticaria) . Vadhan-Raj et al studied the safety profile of ferumoxytol for the treatment of iron deficiency anemia (IDA).…”

“…In another study assessing the toxicity profile of ferumoxytol and ferumoxtran, commercial polyglucose sorbitol carboxymethyl ether-coated IONPs developed for angiography, less than 1% of patients exhibited serious side effects (such as chest pain, hypotension, and dyspnea) while 10−20% of patients exhibited moderate adverse events (such as headache back pain, and urticaria). 39 Vadhan-Raj et al studied the safety profile of ferumoxytol for the treatment of iron deficiency anemia (IDA). The revealed side effects were headaches (detected in 7% of patients), urinary tract infection (5.6% of patients), and any combination of nausea, diarrhea, vomiting, back pain, and dizziness (2−5% of patients).…”